MARLBOROUGH, Mass. , Oct. 23, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) generated net sales of $4.
209 billion during the third quarter of 2024, growing 19.4 percent on a reported basis, 19.5 percent on an operational 1 basis and 18.
2 percent on an organic 2 basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $469 million or $0.32 per share (EPS), compared to $505 million or $0.
34 per share a year ago, and achieved adjusted 3 EPS of $0.63 for the period, compared to $0.50 a year ago.
"Our sustained high performance is a testament to the strength of our talented global team, differentiated portfolio and category leadership strategy," said Mike Mahoney, chairman and chief executive officer, Boston Scientific. "We continue to gain momentum driven by our product pipeline, clinical evidence and commercial execution that position us well for the long term." Third quarter financial results and recent developments: Reported net sales of $4.
209 billion , representing an increase of 19.4 percent on a reported basis, compared to the company's guidance range of 13 to 15 percent; 19.5 percent on an operational basis; and 18.
2 percent on an organic basis, compared to the company's guidance range of 13 to 15 percent, all compared to the prior year period. Reported GAAP net income attributable to Boston Scientific common stockholders of $0.32 per share, compared to the company's guida.
